#USA #Philadelphia #kidney disease #Arctic Therapeutics #Sanos Group

Arctic Therapeutics Secures Significant Funding to Propel Clinical Pipeline

Arctic Therapeutics (ATx), a biopharmaceutical company focusing on developing new treatment avenues through genetic discoveries, has successfully closed an oversubscribed financing round, raising an impressive $21.5 million. This funding will chiefly be directed towards advancing the clinical development of two significant pipeline assets, AT-002 and AT-003, marking a promising expansion of the company’s current projects.

Leadership and Support Behind the Financing

This substantial investment was spearheaded by investment firms such as Pekron, along with the Sanos Group—backed by Investcorp. Other key players in this financing round include the Icelandic investment company Kaldbakur and Landvættir, an endeavor managed by AxUM Securities. This diverse network of investors underscores the confidence in ATx's strategic direction and its scientific innovations.

Ivar Hakonarson, co-founder and CEO of Arctic Therapeutics, expressed gratitude for the support from both new and existing investors. "Having achieved significant milestones with funding from our Series A, this new financing presents us with a unique opportunity to further our developments across our broader pipeline," Hakonarson emphasized.

Advancing Key Programs

The funds raised will be instrumental in progressing AT-002 and AT-003 towards clinical trials. AT-002 is particularly exciting as it serves as a peptide mimetic designed to disrupt the JAK-STAT signaling pathway, primarily aimed at treating autoimmune uveitis. It holds promise for other autoimmune conditions such as lupus and psoriasis. On the other hand, AT-003 functions as a small-molecule modulator targeting cellular dysfunction arising from the aberrant activity of the CLEC16A gene, which is linked with several autoimmune diseases.

Significant Achievements and Future Prospects

This funding follows an earlier Series A round fundraising that totaled approximately $31 million, which was allocated for enhancing AT-001 and AT-004. Both programs have since achieved their respective Phase II clinical development milestones. Hakonarson noted that the journey over the past two years has markedly propelled Arctic Therapeutics into a position geared towards significant advancements in both its lead programs and the newly funded pipeline assets.

With AT-001 focusing on disrupting toxic protein aggregation related to dementia and the promising applications of AT-004 for skin diseases, Arctic Therapeutics is steadily paving the way to deliver safe and effective treatments for diseases that are currently devoid of adequate solutions.

Drawing from Genetic Discoveries

AT-002 and AT-003 are reflective of Arctic Therapeutics’ foundational approach, which emphasizes the application of human genetics to identify disease pathways. Dr. Hakon Hakonarson, another co-founder, highlighted the importance of these genomics-driven solutions, suggesting that the ability to translate genetic findings into viable treatments represents a core strength of the company.

Strategic Collaborations and Future Directions

Earlier in the year, ATx made headlines by acquiring NB-001, a program previously under Nobias Therapeutics, now rebranded as SYN-001, which will aid in addressing neuropsychiatric symptoms related to 22q11.2 deletion syndrome. This acquisition adds another layer of capability to the company's extensive clinical development efforts.

To sum up, Arctic Therapeutics is on a promising trajectory fueled by strong investor confidence and marked by a commitment to address critical medical needs through innovative therapeutic solutions. As clinical trials advance, the healthcare community will undoubtedly be watching closely to see the outcome of these meticulously curated programs targeting both common and rare ailments.